The blood vessel protecting cell response to exercise in people with and without type 1 diabetes

Endothelial progenitor cell (EPCs) response to exercise in individuals with and without type 1 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN63739203

Enrollment

Registered

2019-08-23

Start date

2016-11-01

Completion date

Unknown

Last updated

2024-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 diabetes Nutritional, Metabolic, Endocrine Type 1 diabetes mellitus

Interventions

30 patients with Type 1 diabetes with a wide range of ages, duration of diabetes, fitness, glycaemic control and residual beta-cell function will be recruited. Healthy controls who are age, gender and

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: T1D: 1. Aged 18-65 years old 2. Diagnosed with T1D 3. Treated with exogenous insulin (pump or injection) 4. Free from diabetes complications Healthy: 1. Aged 18-65 years old 2. Free from any chronic diseases

Exclusion criteria

Exclusion criteria: Cardiovascular disease or detection via ECG screening

Design outcomes

Primary

Measure	Time frame
Number of EPCs (CD34+, CD45dim, VEGFR2 and CD34+, CD45dim, CD31+) measured by flow cytometry pre, immediately post and 1-hour post the exercise test between type 1 diabetes and healthy controls	—

Secondary

Measure	Time frame
1. Clinical factors at baseline: 1.1. Fitness measured using graded exercise VO2peak test 1.2. Glycaemic control measured by CGM time in range/in hypoglycaemia/hyperglycaemia and glycaemic variability parameters and HbA1c via commercially available assay test 1.3. Residual beta cell function measured by stimulated serum C-peptide MMTT via commercially available assay test 2. Number of progenitor cells ( (1) CD34+ (2) CD34+, CD45dim (3) CD34+, CD45bright (4) CD34+, CD31+ (5) CD34+, VEGFR2+ (6) CD34+, CD45bright, CD31+ (7) CD34+, CD45bright, VEGFR2+) measured by flow cytometry pre, immediately post and 1-hour post the exercise test in participants with type 1 diabetes and healthy controls 3. Number of EPCs and progenitors expressing chemokine receptors (CXCR4, CXCR7) and the Mean Fluorescence Intensity (MFI) of these chemokine receptors measured using flow cytometry pre, immediately post and 1-hour post the exercise test in type 1 diabetes and healthy control participants	—

Measure

Time frame

1. Clinical factors at baseline: 1.1. Fitness measured using graded exercise VO2peak test 1.2. Glycaemic control measured by CGM time in range/in hypoglycaemia/hyperglycaemia and glycaemic variability parameters and HbA1c via commercially available assay test 1.3. Residual beta cell function measured by stimulated serum C-peptide MMTT via commercially available assay test 2. Number of progenitor cells ( (1) CD34+ (2) CD34+, CD45dim (3) CD34+, CD45bright (4) CD34+, CD31+ (5) CD34+, VEGFR2+ (6) CD34+, CD45bright, CD31+ (7) CD34+, CD45bright, VEGFR2+) measured by flow cytometry pre, immediately post and 1-hour post the exercise test in participants with type 1 diabetes and healthy controls 3. Number of EPCs and progenitors expressing chemokine receptors (CXCR4, CXCR7) and the Mean Fluorescence Intensity (MFI) of these chemokine receptors measured using flow cytometry pre, immediately post and 1-hour post the exercise test in type 1 diabetes and healthy control participants

—

Countries

England, United Kingdom

Contacts

Public ContactDaniel;Guy West;Taylor

;

daniel.west@ncl.ac.uk;g.taylor3@newcastle.ac.uk+44 (0)191 208 7076;+44 (0)1912088264

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 22, 2026